Emerald Advisers LLC boosted its stake in Savara Inc. (NASDAQ:SVRA - Free Report) by 32.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,090,213 shares of the company's stock after buying an additional 757,533 shares during the period. Emerald Advisers LLC owned approximately 1.79% of Savara worth $8,560,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after buying an additional 365,959 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock valued at $482,000 after buying an additional 31,168 shares during the period. Millennium Management LLC raised its holdings in Savara by 71.8% in the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company's stock valued at $1,481,000 after buying an additional 201,599 shares during the period. Deutsche Bank AG raised its holdings in Savara by 6.1% in the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock valued at $2,848,000 after buying an additional 53,054 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its holdings in Savara by 314.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock valued at $217,000 after buying an additional 53,547 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Savara Stock Up 3.6%
Shares of Savara stock traded up $0.09 on Monday, reaching $2.48. 191,975 shares of the company were exchanged, compared to its average volume of 1,266,619. Savara Inc. has a 1-year low of $1.89 and a 1-year high of $5.03. The company has a market cap of $427.78 million, a P/E ratio of -5.20 and a beta of 0.31. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The stock's 50 day moving average price is $2.49 and its 200-day moving average price is $2.72.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). As a group, equities analysts forecast that Savara Inc. will post -0.45 EPS for the current year.
Analyst Upgrades and Downgrades
SVRA has been the subject of several research reports. Guggenheim reaffirmed a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright downgraded Savara from a "buy" rating to a "neutral" rating and dropped their target price for the company from $6.00 to $2.00 in a research report on Thursday, May 29th. Wells Fargo & Company dropped their target price on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Finally, Evercore ISI dropped their target price on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $5.60.
Check Out Our Latest Report on SVRA
Insider Activity at Savara
In related news, Director Richard J. Hawkins acquired 48,225 shares of the stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the transaction, the director owned 115,466 shares in the company, valued at $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.13% of the company's stock.
About Savara
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Stories

Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.